Pfizer

Funds management

Sharpest market rotation in over a decade: Kardinia Capital

The market movement following the announcement of a successful COVID-19 vaccine trial was “a violent rotation” and will not be a one-day event, according to Kardinia Capi...

Funds management

Platinum’s Ogden backs COVID-19 vaccine creators

Platinum International Health Care manager Bianca Ogden is well placed to benefit from the COVID-19 vaccine trials as her fund holds both of the leading players. ...

Funds management

Race ramps up between Pfizer and Moderna

As Moderna becomes the second firm to announce a successful COVID-19 vaccine trial, its shares have risen by more than 400% since the start of the year. ...

Outsider

From the folks who brought you Viagra – a vaccine

Outsider regrets to say that his extensive portfolio of investments does not include pharmaceutical giant Pfizer which at the time of writing has announced that with its ...

Funds management

The funds set to benefit from vaccine deal

As markets react to the news of a successful COVID-19 vaccine trial from US pharma Pfizer and German biotech firm BioNTech, there are just three funds holding these stock...

Funds management

'Long road ahead' despite positive COVID-19 trial

Markets, which are already in a bullish mood due to the incoming Biden administration, are overthinking the positive vaccine news, deVere Group believes. ...

Funds management

Chi-X adds global blue-chip US listed companies

Chi-X Australia, together with Deutsche Bank, has unveiled the next tranche of US listed companies that would be available to investors through its investment vehicle....